Clinical Validation of a Pre-trained and Fine-tuned Model for Analyzing Time-Series Electronic Health Records in Critical Care

August 26, 2026 updated by: Zhao Huiying, Peking University People's Hospital

The goal of this observational study is to validate the generalization capability and predictive performance of the "Time-Series Electronic Health Record Foundation Model (EHR Foundation Model)", which was pre-trained on a large-scale critical care dataset, within the real-world clinical environment of the Intensive Care Unit (ICU) at Peking University People's Hospital. The main question it aims to answer is:

· Based on the "pre-training + fine-tuning" paradigm, whether the EHR foundation model can effectively provide accurate and dynamic prognostic support information in real-world clinical scenarios.

Participants who agree to take part in the research, in addition to completing the signed informed consent form, if the patient's hospital stay is too short, will be obtained information on prognostic outcomes (e.g., 28-day mortality) through telephone follow-up.

Study Overview

Status

Recruiting

Detailed Description

The clinical validation design combines a retrospective cohort study with a prospective cohort study.

Study Type

Observational

Enrollment (Estimated)

4800

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100044
        • Recruiting
        • Peking University People's Hospital
        • Contact:
        • Principal Investigator:
          • Huiying Zhao, PhD
        • Sub-Investigator:
          • Xiaojiang Liu, M.Med
        • Sub-Investigator:
          • Chenxiao Hao, M.Med

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Study Setting: Department of Critical Care Medicine (ICU), Peking University People's Hospital.

Data Source and Time Period:

Retrospective Validation Cohort: Electronic health record data from all patients admitted to the ICU of Peking University People's Hospital between January 1, 2009 and December 31, 2025. This dataset will be used for local fine-tuning and internal validation of the model.

Prospective Validation Cohort: Newly diagnosed cases admitted to the ICU of Peking University People's Hospital from March 1, 2026 to December 31, 2026 (following project initiation). This dataset will be used for external independent validation of the model.

Description

Inclusion Criteria:

  • Age ≥ 18 years, no gender restriction;
  • ICU length of stay ≥ 24 hours (to ensure sufficient time-series monitoring data for model generation);
  • Complete electronic health record data, including baseline demographic characteristics and at least one complete laboratory test record after ICU admission.

Exclusion Criteria:

  • Patients who are transferred out or die within 24 hours of ICU admission;
  • Duplicate admission records for non-initial ICU admissions (only the initial ICU admission record is retained to ensure independence);
  • Severe deficiency in core data (e.g., absence of major vital sign recordings or > 50% missing key laboratory test results);
  • Patients with abandonment of treatment or discharge against medical advice, leading to inability to ascertain the definitive clinical outcome.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Non-survivor group
Patients confirmed to have died within 28 days (outcome obtained from hospital records or telephone follow-up).
Survivor group
Patients confirmed to have survived beyond 28 days (outcome obtained from hospital records or telephone follow-up).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
In-hospital Mortality
Time Frame: The endpoints are patient discharge or death. For prognostic outcomes (e.g., 28-day mortality), if the patient's hospital stay is insufficient, the outcome will be obtained through telephone follow-up.
Death events occurring during the patient's current hospitalization.
The endpoints are patient discharge or death. For prognostic outcomes (e.g., 28-day mortality), if the patient's hospital stay is insufficient, the outcome will be obtained through telephone follow-up.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

August 26, 2026

First Submitted That Met QC Criteria

August 26, 2026

First Posted (Actual)

August 31, 2026

Study Record Updates

Last Update Posted (Actual)

August 31, 2026

Last Update Submitted That Met QC Criteria

August 26, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe